Patients with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) are at a significantly increased risk of developing colorectal cancer (CRC) compared to those with UC alone ...

"Our deep expertise in treating liver disease has delivered the first and only treatment for hepatitis delta and the first treatment for primary biliary cholangitis that has demonstrated ...

In this study, researchers created a new animal model, the pyogenic spondylodiscitis-posterior fixation model rat, and investigated the mechanism by which posterior fixation suppresses infection.

Chemomab Therapeutics announces Phase 3 trial design for nebokitug, aiming for FDA approval in primary sclerosing cholangitis.

A pyogenic liver abscess is a collection of pus forming in the liver, usually stemming from a bacterial infection. Read more.

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - Designation based on positive interim analysis of Phase 2b VANTAGE study ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows ...

The FDA has granted accelerated approval to Livdelzi (seladelpar), Gilead’s treatment for primary biliary cholangitis (PBC) in adults who either have an inadequate response to ursodeoxycholic acid ...

Learn about the symptoms and causes of pyogenic granulomas. This article also looks at treatment options, diagnosis, complications, and more.

Gilead Sciences’ primary biliary cholangitis candidate seladelpar and Ipsen’s PBC asset elafibranor both showed encouraging Phase III results Wednesday, as they face looming FDA decision dates.